Almirall, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
$2B
Website

A Study of of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2024-07-29
Last Posted Date
2024-07-29
Lead Sponsor
Almirall, S.A.
Target Recruit Count
520
Registration Number
NCT06526182
Locations
🇪🇸

Hospital del Mar - Parc de Salut Mar, Barcelona, Spain

🇪🇸

Hospital General Universitario Dr. Balmis, Alicante, Spain

🇪🇸

Hospital Universitario Clínico San Cecilio, Granada, Spain

and more 1 locations

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

First Posted Date
2024-07-05
Last Posted Date
2024-10-18
Lead Sponsor
Almirall, S.A.
Target Recruit Count
72
Registration Number
NCT06488209
Locations
🇺🇸

Doral Medical Research, Miami, Florida, United States

🇺🇸

Jennifer Parish, MD, Philadelphia, Pennsylvania, United States

🇺🇸

ICON Early Phase Services, LLC, San Antonio, Texas, United States

A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting

Recruiting
Conditions
Interventions
First Posted Date
2024-07-05
Last Posted Date
2024-07-05
Lead Sponsor
Almirall, S.A.
Target Recruit Count
50
Registration Number
NCT06488170
Locations
🇨🇿

University Hospital Ostrava, Ostrava, Czechia

🇨🇿

Fakultní nemocnice Plzeň, with its registred seat at Edvarda Beneše, Pilsen, Czechia

🇨🇿

University Hospital in Motol, Praha, Czechia

and more 1 locations

A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2024-01-11
Last Posted Date
2024-10-28
Lead Sponsor
Almirall, S.A.
Target Recruit Count
92
Registration Number
NCT06200597
Locations
🇺🇸

ICON Phase 1 unit Lenexa, Lenexa, Kansas, United States

A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2023-11-18
Last Posted Date
2024-05-01
Lead Sponsor
Almirall, S.A.
Target Recruit Count
270
Registration Number
NCT06135415
Locations
🇩🇪

Site 2, Hamburg, Germany

🇪🇸

Site 15, Valencia, Spain

🇪🇸

Site 12, Barcelona, Spain

and more 13 locations

A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

Recruiting
Conditions
Interventions
First Posted Date
2023-09-08
Last Posted Date
2024-01-31
Lead Sponsor
Almirall, S.A.
Target Recruit Count
110
Registration Number
NCT06029257
Locations
🇦🇹

Medizinische Universität Graz, Graz, Styria, Austria

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Recruiting
Conditions
Interventions
First Posted Date
2023-09-08
Last Posted Date
2024-01-31
Lead Sponsor
Almirall, S.A.
Target Recruit Count
50
Registration Number
NCT06030076
Locations
🇦🇹

Gesundheitszentrum Citypark Graz, Graz, Styria, Austria

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2023-08-14
Last Posted Date
2024-04-25
Lead Sponsor
Almirall, S.A.
Target Recruit Count
240
Registration Number
NCT05990725
Locations
🇩🇪

Site 3, Hamburg, Germany

🇩🇪

Site 23, Heidelberg, Germany

🇩🇪

Site 8, Hamburg, Germany

and more 30 locations

Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2023-06-23
Last Posted Date
2024-04-24
Lead Sponsor
Almirall, S.A.
Target Recruit Count
200
Registration Number
NCT05916365
Locations
🇩🇪

Investigator Site 11, Münster, Nordrhein-Westfalen, Germany

🇩🇪

Investigator Site 7, Darmstadt, Hessen, Germany

🇩🇪

Investigator Site 9, Osnabrück, Lower Saxony, Germany

and more 29 locations

A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults

Active, not recruiting
Conditions
Interventions
First Posted Date
2023-04-13
Last Posted Date
2024-07-01
Lead Sponsor
Almirall, S.A.
Target Recruit Count
291
Registration Number
NCT05811234
Locations
🇬🇧

UK03, Crewe, United Kingdom

🇬🇧

UK06, Chipping Norton, United Kingdom

🇬🇧

UK08, Cockermouth, United Kingdom

and more 34 locations
© Copyright 2024. All Rights Reserved by MedPath